Abdou Sherif
Known title: Chief Executive OfficerCIK: 0001890129
Abdou Sherif's purchase track record
Abdou Sherif has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/12/2023 | PIII | $284K | -24.7% | -48.7% | +7.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PIII | ▼ Sell | Other | 483,868 | — | 1/9/2024 | View on chart |
| PIII | ▼ Sell | Tax Withholding | 483,868 | $682K | 12/31/2023 | View on chart |
| PIII | ▲ Buy | Grant | 1,500,000 | $0 | 8/4/2023 | View on chart |
| PIII | ▲ Buy | Open Market | 108,225 | $284K | 5/12/2023 | View on chart |
| PIII | ▲ Buy | Grant | 9,626,075 | $9266.2M | 12/3/2021 | View on chart |
| PIII | ▲ Buy | Grant | 3,058,479 | $935.4M | 12/3/2021 | View on chart |
| PIII | ▲ Buy | Grant | 1,408,437 | $198.4M | 12/3/2021 | View on chart |
| PIII | ▲ Buy | Grant | 9,626,075 | $9266.2M | 12/3/2021 | View on chart |
| PIII | ▲ Buy | Grant | 3,058,479 | $935.4M | 12/3/2021 | View on chart |
| PIII | ▲ Buy | Grant | 1,408,437 | $198.4M | 12/3/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
PIII appoints new Chief Clinical Officer
P3 Health Partners announced the appointment of a new Chief Clinical Officer. The executive will oversee clinical operations and strategy for the company. This addition brings additional expertise as the firm pursues its growth plans. The stock is currently trading with a low RSI and near its recent support level.
PIII appoints new Chief Clinical Officer. P3 Health Partners announced the appointment of a new Chief Clinical Officer. The executive will oversee clinical operations and strategy for the company. This addition brings additional expertise as the firm pursues its growth plans. The stock is currently trading with a low RSI and near its recent support level.